These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1677151)

  • 1. Desferrioxamine for Alzheimer's disease.
    Lancet; 1991 Aug; 338(8762):324-6. PubMed ID: 1677151
    [No Abstract]   [Full Text] [Related]  

  • 2. Desferrioxamine and Alzheimer's dementia.
    King RG
    Med J Aust; 1985 Mar; 142(6):352. PubMed ID: 4038776
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
    Percy ME; Kruck TP; Pogue AI; Lukiw WJ
    J Inorg Biochem; 2011 Nov; 105(11):1505-12. PubMed ID: 22099160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron and aluminum in Alzheimer's disease.
    Di Lorenzo F; Di Lorenzo B
    Neuro Endocrinol Lett; 2013; 34(6):504-7. PubMed ID: 24378455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
    Kruck TP; Fisher EA; McLachlan DR
    Clin Pharmacol Ther; 1990 Oct; 48(4):439-46. PubMed ID: 2225704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 13. Intramuscular desferrioxamine in patients with Alzheimer's disease.
    Crapper McLachlan DR; Dalton AJ; Kruck TP; Bell MY; Smith WL; Kalow W; Andrews DF
    Lancet; 1991 Jun; 337(8753):1304-8. PubMed ID: 1674295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic factors and aluminum are possible causes of Alzheimer's disease].
    Lake S; Winblad B
    Lakartidningen; 1991 Apr; 88(14):1279-81. PubMed ID: 2016974
    [No Abstract]   [Full Text] [Related]  

  • 17. Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment.
    Kurokawa K; Marumo F; Ogura Y; Ono T; Suzuki M
    J UOEH; 1987 Mar; 9 Suppl():133-9. PubMed ID: 3602744
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion specific chelation.
    Kruck TP; McLachlan DR
    Prog Clin Biol Res; 1989; 317():1155-67. PubMed ID: 2690090
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.